Setmelanotide
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Setmelanotide |
| DrugBank ID | DB11700 |
| Brand Names (EU) | Imcivree |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 92.25% |
Approved Indication (EMA)
IMCIVREE is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 2 years of age and above.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | migraine disorder | 92.25% | DL |
| 2 | migraine with brainstem aura | 91.68% | DL |
| 3 | non-syndromic esophageal malformation | 89.60% | DL |
| 4 | esophageal disease | 88.38% | DL |
| 5 | amenorrhea (disease) | 86.01% | DL |
| 6 | cauda equina syndrome | 83.00% | DL |
| 7 | obsolete neurogenic bladder (disease) | 82.21% | DL |
| 8 | esophageal ulcer | 81.44% | DL |
| 9 | Ambras type hypertrichosis universalis congenita | 81.23% | DL |
| 10 | pituitary dwarfism | 81.07% | DL |
| 11 | migraine with or without aura, susceptibility to | 80.37% | DL |
| 12 | atrophoderma vermiculata | 79.98% | DL |
| 13 | malformation syndrome with odontal and/or periodontal component | 78.91% | DL |
| 14 | syndrome with a Dandy-Walker malformation as major feature | 78.38% | DL |
| 15 | isolated genetic hair shaft abnormality | 78.00% | DL |
| 16 | erectile dysfunction (disease) | 77.93% | DL |
| 17 | hypertrichosis (disease) | 77.89% | DL |
| 18 | ulerythema ophryogenesis | 76.67% | DL |
| 19 | acne (disease) | 74.14% | DL |
| 20 | adrenal gland hyperfunction | 72.82% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.